The effect of treatment with high dose vitamin D on airway inflammation in non-atopic asthma.
Phase 3
Completed
- Conditions
- Asthma10006436bronchitis
- Registration Number
- NL-OMON32451
- Lead Sponsor
- Medisch Centrum Leeuwarden
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 58
Inclusion Criteria
Non-atopic asthma (negative alatop test and pulmonologist's diagnosis of asthma)
neutrophilic and/or eosinophilic inflammation in induced sputum (>53% neutrophils and/or >3% eosinophils)
>=18 yrs
Documented reversibility in FEV1 of > 12% predicted OR airway hyperresponsiveness to inhaled methacholine
Exclusion Criteria
Allergy
Pregnancy
Contra-indications regarding vitamin D use: hypercalcaemia, malignancy, sarcoidosis, history of kidneystones.
Patients with smoking history of >10 packyears and persistent airflow obstruction (post bronchodilator FEV1<80%pred): excluded if reversibility in FEV1 < 12% predicted OR TLCO<80%pred.
Vitamin D use prior to this study.
Other pulmonary diseases
Vitamin D3 level > 100 nmol/l
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method